Immunosuppressive Agents
"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 21 | 2 | 23 | | 1997 | 7 | 3 | 10 | | 1998 | 5 | 5 | 10 | | 1999 | 10 | 6 | 16 | | 2000 | 10 | 7 | 17 | | 2001 | 15 | 5 | 20 | | 2002 | 9 | 3 | 12 | | 2003 | 11 | 10 | 21 | | 2004 | 13 | 10 | 23 | | 2005 | 17 | 12 | 29 | | 2006 | 8 | 2 | 10 | | 2007 | 8 | 10 | 18 | | 2008 | 9 | 7 | 16 | | 2009 | 11 | 16 | 27 | | 2010 | 14 | 10 | 24 | | 2011 | 9 | 11 | 20 | | 2012 | 12 | 11 | 23 | | 2013 | 21 | 7 | 28 | | 2014 | 14 | 13 | 27 | | 2015 | 17 | 7 | 24 | | 2016 | 12 | 15 | 27 | | 2017 | 17 | 10 | 27 | | 2018 | 6 | 8 | 14 | | 2019 | 14 | 9 | 23 | | 2020 | 13 | 14 | 27 | | 2021 | 13 | 9 | 22 | | 2022 | 0 | 11 | 11 | | 2023 | 2 | 13 | 15 | | 2024 | 7 | 23 | 30 | | 2025 | 13 | 4 | 17 | | 2026 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Bock M, Benz E, Blanchette E, Goebel J, Wedermyer G, Roark C, Wachs M, Adams M, Sundaram S, Chandran M. Excellent Long-Term Outcome in a Staged, Simultaneous Liver-Kidney Transplantation of a Highly Sensitized Pediatric Patient With B and T Cell Positive Crossmatch. Pediatr Transplant. 2026 Nov; 30(11).
-
Virupakshaiah A, Schoeps VA, Race J, Gambrah-Lyles C, Chang G, Waltz M, Nasr P, Moseley CE, Zamvil SS, Edwards AR, Francisco C, Casper TC, Rose JW, Flanagan EP, Rodriguez M, Tillema JM, Chitnis T, Gorman MP, Benson LA, Graves JS, Rensel M, Abrams AW, Krupp LB, O'Neill KA, Lotze TE, Fisher KS, Shukla NM, Aaen GS, Wheeler YS, Schreiner TL, Waldman AT, Chong J, Waubant E, Mar SS. Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology. 2026 Oct 27; 107(8):e218508.
-
Goldberg AR, Nastasio S, Mack CL. From Controversy to Clarity: The New Landscape of Pediatric Autoimmune Hepatitis Care. Clin Liver Dis. 2026 Nov; 30(4):925-941.
-
Thomson D, Dammann A, Benz E, Blanchette E, Bock M, Christofferson ES. Substance Use Patterns in Pediatric Solid Organ Transplant Candidates: Impact After Transplant. Pediatr Transplant. 2026 Aug; 30(8):e70427.
-
DiPaola F, Feldman A, Ng V, Antala S, Bucuvalas J, Ebel N, Gupta N, Halma J, Kohli R, Leung D, Lobritto S, Peters A, Squires J, Perito E. Prevalence of a Composite Outcome to Capture Child and Liver Health One Year After Pediatric Liver Transplantation in the Starzl Network. Pediatr Transplant. 2026 Jul; 30(7):e70402.
-
Vasilenko N, Ruschil C, Stadelmaier J, Tieck MP, Schembecker S, Owens GP, Bennett JL, Berthele A, Ziemann U, Poli S, Snaidero N, Nahnsen S, Jarboui MA, Bichmann L, Gabernet G, Kowarik MC. Extensive peripheral immunoglobulin repertoire analyses in people with multiple sclerosis reveal disease-specific signatures and distinct treatment effects of disease modifying drugs. J Neuroinflammation. 2026 Apr 14; 23(1).
-
Campa-Carranza JN, Capuani S, Willman MA, Rabassa A, Joubert AL, Bo T, Franco L, Conte M, Anaya-García AL, Rome GE, Ouni R, Seaborne HJ, Caffey CA, Berman DM, Zheng J, Paez-Mayorga J, Chua CYX, Chen SH, Kenyon NS, Grattoni A. Profiling Localized Immunomodulation and Drug Biodistribution within a Subcutaneous Vascularized Niche for Cell Transplantation. Adv Sci (Weinh). 2026 May; 13(28):e20914.
-
Alabi A, Kerr JS, Shah M, Khan A, Ma JD, Suhandynata RT, Momper JD, Tsunoda SM. Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended-Release Tacrolimus (LCPT) Using Grapefruit Juice. Clin Pharmacol Drug Dev. 2026 01; 15(1):e70016.
-
Chastain DB, Thompson GR, Henao-Martínez AF. Glucocorticoids, Concomitant Immunosuppression, and Pneumocystis jirovecii Pneumonia Prophylaxis Among US Adults. Clin Infect Dis. 2025 12 24; 81(5):1015-1018.
-
Harris KJR, Ludtke EA, Goldberg B, McCall NN, Hewlett JC, Wilfong EM. Tacrolimus as first-line therapy in a US cohort of idiopathic inflammatory myopathies related interstitial lung disease. Rheumatology (Oxford). 2025 12 01; 64(SI):SI179-SI183.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|